phone

Male Hypogonadism - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 100
  • Category: Pharmaceuticals
  • Country: Global
Male Hypogonadism - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2017, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesnt produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 1, 4, 4, 2, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Male Hypogonadism - Overview 6
Male Hypogonadism - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Male Hypogonadism - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Male Hypogonadism - Companies Involved in Therapeutics Development 22
Antares Pharma Inc 22
Clarus Therapeutics Inc 22
EndoCeutics Inc 23
Ferring International Center SA 23
Lipocine Inc 24
M et P Pharma AG 24
Medlab Clinical Ltd 25
Merck & Co Inc 25
Mereo Biopharma Group Plc 26
Repros Therapeutics Inc 26
TesoRx Pharma LLC 27
The Female Health Company 27
Viramal Ltd 28
Male Hypogonadism - Drug Profiles 29
BGS-649 - Drug Profile 29
corifollitropin alfa - Drug Profile 31
enclomiphene citrate - Drug Profile 33
IAS-167A - Drug Profile 47
Kisspeptin-10 - Drug Profile 48
leuprolide acetate - Drug Profile 49
Libidua - Drug Profile 50
LPCN-1111 - Drug Profile 51
MSS-722 - Drug Profile 53
testosterone - Drug Profile 54
testosterone - Drug Profile 60
testosterone - Drug Profile 61
testosterone - Drug Profile 63
testosterone enanthate - Drug Profile 65
testosterone propionate - Drug Profile 70
testosterone undecanoate - Drug Profile 71
testosterone undecanoate - Drug Profile 75
testosterone undecanoate - Drug Profile 80
testosterone undecanoate - Drug Profile 81
testosterone undecanoate - Drug Profile 82
testosterone undecanoate - Drug Profile 83
testosterone undecanoate - Drug Profile 84
Male Hypogonadism - Dormant Projects 85
Male Hypogonadism - Discontinued Products 86
Male Hypogonadism - Product Development Milestones 87
Featured News & Press Releases 87
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List Of Tables


Number of Products under Development for Male Hypogonadism, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017
Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017
Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017
Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017
Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017
Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017
Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017
Male Hypogonadism - Pipeline by The Female Health Company, H2 2017
Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017
Male Hypogonadism - Dormant Projects, H2 2017
Male Hypogonadism - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Male Hypogonadism, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Canada General Surgery Outlook to 2023 - Airway Stenting Procedures, Bariatric Surgery Procedures, Biopsy Procedures, Female Sterilization Procedures, Gastric Balloon Procedures, Enteral Stenting Procedures and Others GlobalDatas new report, Canada General

View Report

Brazil General Surgery Outlook to 2023 - Airway Stenting Procedures, Bariatric Surgery Procedures, Biopsy Procedures, Female Sterilization Procedures, Gastric Balloon Procedures, Enteral Stenting Procedures and Others GlobalDatas new report, Brazil General

View Report

Mexico General Surgery Outlook to 2023 - Airway Stenting Procedures, Bariatric Surgery Procedures, Biopsy Procedures, Female Sterilization Procedures, Gastric Balloon Procedures, Enteral Stenting Procedures and Others GlobalDatas new report, Mexico General

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports